The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial.
 
Imanol Martinez
No Relationships to Disclose
 
Kenneth Kernan
Consulting or Advisory Role - Astellas Pharma; Bayer; Johnson & Johnson; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Johnson & Johnson; Pfizer
 
Piotr Piasecki
No Relationships to Disclose
 
Joelle P. Hamilton
Honoraria - Bayer; Janssen
Speakers' Bureau - Bayer; Janssen
Research Funding - Bayer; Janssen
 
Chee Goh
No Relationships to Disclose
 
Peter Árkosy
No Relationships to Disclose
 
Sarah Needleman
No Relationships to Disclose
 
Raffaele Ratta
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer
Consulting or Advisory Role - Astellas Pharma; Ipsen; MSD; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Pfizer
 
Mehrnaz Tadayon
No Relationships to Disclose
 
Marie Watissée
Stock and Other Ownership Interests - Takeda
Consulting or Advisory Role - Tavanta Therapeutics
 
Elizabeth Duus
Employment - Tavanta Therapeutics
Stock and Other Ownership Interests - Tavanta Therapeutics
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; Exelixis; Genzyme; Gilead Sciences; Hengrui Pharmaceutical; Hinova Pharmaceuticals; Janssen Oncology; Merck; Pfizer; Tavanta Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Seagen (Inst)